Alvotech, not content to line up behind other Humira biosims, sues AbbVie over 'wrongful monopoly'

AbbVie has inked a series of patent settlements with biosimilar makers allowing U.S. copycat launches to the world's bestselling medicine in 2023. With the first Humira biosim launches a little under 2 years away, Alvotech is hoping to find another route to the market.

Alvotech Tuesday morning said it had filed a federal lawsuit against AbbVie seeking to end the pharma juggernaut's "wrongful monopoly" on the world's best-selling drug.